-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Taipei, October 18, 2021 /PRNewswire The data from the Phase II clinical trial of MVC-COV1901 vaccine (referred to as "high-end vaccine") showed good immunogenicity and safety
The study was conducted from December 30, 2020 to April 2, 2021.
The test results showed that based on wild-type SARS-CoV-2 GMT, the seroconversion rate of the MVC-COV1901 group on day 57 was 99.
The SARS-CoV-2 antigen design used in the MVC-COV1901 vaccine was approved by the National Institutes of Health (NIH), in which a series of genetic modifications were made to the S-2P fusion prospine protein
In summary, the interim analysis shows that the MVC-COV1901 vaccine has good safety and a good neutralizing antibody titer
The results of this research have become the basis for immune bridging, enabling the MVC-COV1901 vaccine to obtain an "emergency use authorization" in Taiwan and help support subsequent development progress
Introduction to High-end Vaccine Biologics Co.
High-end Vaccine Biologics Co.